Summary The serum and urine concentrations of a tumour-associated trypsin inhibitor, TATI, were determined by radioimmunoassay in patients with pancreatic cancer and with benign pancreatic and biliary diseases. Elevated serum levels (>20 pug1-1) were found in 85% of the patients with pancreatic cancer, and elevated urine levels (>50pgg-1 creatinine) in 96% of the patients. Immunohistochemical staining of pancreatic lesions showed that half of the pancreatic tumours expressed TATI, but the pancreatic tissue adjacent to a carcinoma always stained stronger than the carcinoma. It therefore seems that the main source of TATI in serum and urine of patients with pancreatic cancer are the normal acini and not the tumour tissue. In pancreatitis the staining was intense and clearly stronger than in normal pancreas.
makes the possibility of pancreatic cancer less likely. Serial assay of TATI in serum from three patients with surgically removed pancreatic cancer showed elevation of the TATI level at the time of detection of recurrence. However, high serum and urine levels were also seen in pancreatitis and in benign extrahepatic cholestasis. Thus TATI is a sensitive, although not specific, indicator of pancreatic and biliary disease, but the use of TATI as a tumour marker in the primary diagnosis of pancreatic cancer is limited.
Immunohistochemical staining of pancreatic lesions showed that half of the pancreatic tumours expressed TATI, but the pancreatic tissue adjacent to a carcinoma always stained stronger than the carcinoma. It therefore seems that the main source of TATI in serum and urine of patients with pancreatic cancer are the normal acini and not the tumour tissue. In pancreatitis the staining was intense and clearly stronger than in normal pancreas.
The tumour-associated trypsin inhibitor, TATI, is a 6000 dalton peptide, isolated from the urine of a patient with ovarian cancer Huhtala et al., 1982) . Elevated concentrations have been found in the urine of patients with gynaecological cancer, in amniotic fluid and in some extracts from malignant tumours . TATI levels are also elevated in patients with pancreatitis and severe pneumonia (Huhtala et al., 1983) . Determination of the N-terminal amino acid sequence of TATI has revealed that it is closely related or identical to the pancreatic secretory trypsin inhibitor (PSTI) (Kazal et al., 1948; Bartelt et al., 1977; Huhtala et al., 1982) . Elevated levels of PSTI have been found in serum and urine of patients with pancreatitis (Eddeland & Ohlsson, 1978; Kitahara et al., 1980; Ogawa et al., 1980) , and in serum of patients both with pancreatic cancer and various other malignancies Murata et al., 1983) . Immunohistochemically PSTI has been demonstrated in normal acinar cells, but could not be detected in tissue specimens of pancreatic cancer (Marks et al., 1984) .
In the present work that TATI levels in serum Radioimmunoassay of TA TI The concentration of TATI in serum and urine was determined by radioimmunoassay as previously described (Huhtala et al., 1983) . The serum and urine samples were stored at -20°C or lower temperature until assayed. To avoid the effect of variation in urinary excretion rate, the urinary concentration of TATI was correlated to the urinary creatinine concentration. The cut-off level in serum was 20 gIg and in urine 50 ,gg 1 creatinine.
Immunodiffusion
The immunological identity of TATI in the urine of patients with pancreatic cancer, pancreatitis and benign biliary disease was studied by immunodiffusion. This was performed on 1Ox 1O cm agar plates using 0.9% agar in phosphate-buffered (10 mmol I-l, pH 7.4) saline (150 mmol l-1) (PBS) containing 4% polyethylene glycol 6000 (Fluka AG, Buchs, Switzerland).
Determination of CA 19-9, CEA, CRP, amylase, bilirubin and alkaline phosphatase The TATI levels were compared to CA 19-9, that has been demonstrated to be useful as a tumour marker in pancreatic cancer (Haglund et al., 1986) , and to CEA. The CRP level was determined as an indicator of acute inflammation. As indicators of juandice, extrahepatic cholestasis and of pancreatitis serum bilirubin, total alkaline phosphatase and amylase were recorded.
The concentration of CA 19-9 in serum was measured using the CA 19-9 RIA obtained from Centocor (Malvern, PA, USA), and carcinoembryonic antigen (CEA) using the Abbott-CEA-RIA Diagnostic Kit (Abbott, Wiesbahn, West Germany). A cut-off value of 37Uml-1 was used for CA 19-9 and 2.5ngml-I for CEA. CRP was determined by immunoturbidometry using an IL Multistat centrifugal analyser. Antiserum and CRP standard were purchased from Orion Diagnostica (Helsinki, Finland). A cut-off level of 10mg I1 was used. Serum amylase, bilirubin and alkaline phosphatase values were obtained from clinical records, when available. Standard cut-off values of 300 U ml -1, 20 mol 1 and 280 U ml 1, respectively, were used.
Staining procedure Five ,um thick sections were deparaffinized, hydrated and treated with 0.4% pepsin (2500 FIP-U g-1, Merck, Darmstadt, West Germany) in 0.01 NHCl for 1 h at 37°C. The sections were incubated in 0.5% hydrogen peroxide in methanol to block endogenous peroxidase. The sections were then reacted with serum from rabbits immunized with purified TATI. Bound antibody was detected with an avidin-biotin complex assay (ABC, Vectastain) or an indirect immunoperoxidase technique. In the ABC-assay sections were successively treated with non-immune horse serum, serum containing TATI antibodies (1:50), biotinylated anti-mouse immunoglobulin antiserum, avidin, and biotinylated horseradish peroxidase complex. The sections were finally exposed to 3-amino-9-ethyl-carbazole (AEC) and hydrogen peroxide. Using the indirect staining technique sections were incubated with non-immune swine serum (1:20), primary antibody (1:20), swine antirabbit peroxidase conjugate (Dako, Copenhagen, Denmark) (1:100), AEC and hydrogen peroxide. Each step was followed by washing in PBS. All sections were counterstained with hematoxylin.
Enhancement of the staining using pepsin pretreatment was shown in a test series. Staining with non-immune rabbit serum and with PBS were used as negative controls. A known positive specimen was used as a positive control in each series.
TA TI in serum and urine in pancreatic cancer Twenty-nine of 34 patients (85%) with pancreatic cancer had a serum TATI level above 20 g 1-1.
The median value was 38ygl-1 and the range 14-1419ugl-1. Elevated levels were also seen in serum of five out of six patients with a local, resectable tumour (Figure 1) .
Serial samples were obtained from 3 patients. One had an elevated preoperative serum TATI level, which decreased after surgical removal of the tumour, remained moderately elevated and increased again at the time the recurrence was clinically detected. In the other two patients the initial serum TATI level was normal and increased only moderately at the time of detection of the recurrence (Figure 2) . Twenty-six of 27 patients (96%) had an elevated urine TATI level (>50 g g-1 creatinine). The median value was 173 pg g-1 creatinine and the range 47-25,200 pg g-1 creatinine. Urine samples were available from 2 patients with a local tumour, both of which had an elevated TATI level ( Figure  3 ). Serial urine samples were available from only one patient. The urine TATI concentration stayed at the same level postoperatively and did not markedly increase although a recurrence was detected. Both well and poorly differentiated ductal adenocarcinomas were associated with elevated levels of TATI in serum and urine. One patient with an anaplastic carcinoma had a normal serum level and one patient with an islet cell carcinoma had a normal serum but an elevated urine TATI, whereas one patient with a carcinoid tumour of the pancreas had a very high serum TATI concentration and a moderately elevated urine level.
TA TI in serum and urine in benign diseases Twenty-one of 25 patients (84%) with pancreatitis had an increased serum TATI concentration. The TA TI in histological specimens Normal pancreas Acini stained positively in normal pancreas, but rather weakly in some specimens. Predominantly the apical parts of the acinar cells were positive, but in some cases a diffuse intracytoplasmic staining was seen.
Occasionally the brush border of the ductal epithelium was stained. Langerhans' islets were always negative ( Figure 5 ). Normal pancreatic tissue adjacent to chronic pancreatitis or carcinomas usually stained more strongly than normal pancreas. In two of these cases even occasional cells within Langerhans' islets stained.
Pancreatitis Acinar cells had a strong intracytoplasmic staining. The distribution was typically diffuse, but in places the apical parts of the cells stained more strongly. Positive intracytoplasmic granules were seen in part of the cells, especially in chronic pancreatitis. The staining was stronger in pancreatitis than in normal pancreas. Acute pancreatitis stained more intensely than chronic pancreatitis. Part of both small and large ducts stained positively at the luminal border ( Figure 6 ). Islets were negative in all but two cases of chronic pancreatitis, where occasional positive cells were seen.
Well to moderately differentiated adenocarcinomas Nineteen out of 35 primary tumours expressed TATI. The positivity was predominantly seen in the apical parts of the cells, where occasionally intensely stained positive granules were seen ( Figure  7A ). In places the intracytoplasmic staining was diffuse. The positive staining was focal, and less intense than in adjacent normal pancreatic tissue ( Figure 7B ). Four liver metastases and one metastasis from the omentum were negative. One metastasis in the wall of the small intestine was focally positive. In one patient both the primary tumour and a liver metastasis were negative. Poorly differentiated and anaplastic carcinomas All 6 primary and metastatic poorly differentiated adenocarcinomas, as well as all 5 primary and metastatic anaplastic carcinomas were negative.
Cystic tumours The intracytoplasmic mucin stained positively in all 4 mucinous cystadenomas ( Figure  8 ), but in none of the 3 mucinous cystadenocarcinomas. In 2 cystadenomas the staining was intense and widely distributed, but in the other 2 weaker and focal. All 3 serous cystadenomas were negative. One carcinoid tumour of the pancreas as well as all benign and malignant islet cell tumours were negative.
Comparison between expression in tissue and serum and urine concentration There was no correlation between the immunohistochemical expression of TATI of the tumour and the serum and urine TATI concentrations (Table I) . Many negative tumours were associated with elevated serum and/or urine levels. . Pancreatic secretory trypsin inhibitor, PSTI, was originally thought to be produced only by the pancreas. However, the excretion of TATI is elevated in urine of patients with gynaecological cancer , and immunohistochemically PSTI has been demonstrated in many tissues Murata et al., 1983) . Recently normal levels of TATI have been found in serum after total pancreatectomy, further indicating an extrapancreatic production of this trypsin inhibitor (Halila et al., 1985) . We now show that the trypsin inhibitor in urine of patients with pancreatic cancer, acute pancreatitis, benign extrahepatic cholestasis and ovarian cancer are immunologically identical.
Immunohistochemical studies of pancreatic tissue have previously been performed with antibodies against PSTI, demonstrating PSTI in acinar glands but not in pancreatic cancer (Marks et al., 1984) . In our study about half of the pancreatic cancers were positive for TATI, but the expression was often weak and usually only focal, and the adjacent acinar structures stained stronger than the carcinoma. On the basis of these findings it seems that the main source of TATI in serum and urine of patients with pancreatic cancer are the acini and not the tumour tissue. This is further supported by the elevated serum and urine levels of TATI in patients with immunohistochemically TATI negative tumours. In one metastasis of a pancreatic carcinoma a few positive cells were seen, in all other cases the metastases were negative.
The tissue expression of TATI in pancreatic tissue adjacent to a carcinoma is stronger than the expression in normal pancreas, possibly because of an obstruction of pancreatic ducts with congestion of material normally secreted. An increased production of material normally secreted. An increased production of TATI by the acinar cells is also possible. In acute pancreatitis the increased proteolytic activity might induce an increased production of proteolytic inhibitors. On the other hand, the secretion could be decreased due to tissue oedema. The source of the elevated TATI levels seen in benign extrahepatic cholestasis is unknown. A bile duct stone in the distal portion of the common bile duct may cause obstruction of both the common bile duct and the pancreatic duct, which may explain the high serum and urine levels of TATI in some patients. On the other hand, TATI can also be found immunohistochemically in biliary epithelium (Haglund et al., unpublished) .
Although the main source of the high concentrations of TATI seems to be the adjacent benign tissue, some tumours apparently are able to produce this trypsin inhibitor. The capacity seems to be limited to well differentiated carcinomas. The benign mucinous cystic tumours expressed TATI, whereas the mucinous cystadenocarcinomas, as well as the serous cystadenomas were negative. All mucinous cystic tumours of the pancreas are regarded potentially malignant (Compagno & Oertel, 1978) . It is possible that the inability to produce TATI correlates with the degree of malignancy of mucinous cystic tumours.
As a conclusion, a negative TATI level, especially in urine, strongly speaks against pancreatic cancer, but in clinical practice the low specificity limits the use of TATI as a tumour marker to differentiate between benign and malignant pancreatic diseases.
